Overview
Malignant hypertensive chronic kidney disease (CKD) is characterized by severe hypertension leading to progressive kidney damage and dysfunction, often involving renal fibrosis and structural changes such as nephroangiosclerosis. 2Diagnosis
Clinical Presentation: Hypertension with signs of kidney dysfunction (e.g., proteinuria, decreased GFR).
Diagnostic Tests: Renal biopsy for definitive diagnosis, especially in atypical cases; ambulatory blood pressure monitoring to assess masked hypertension. 3
Histopathology: Renal biopsy reveals features like nephroangiosclerosis, tubulointerstitial fibrosis, and glomerular changes. 2
Blood Pressure Assessment: Clinic BP may underestimate true BP control; ambulatory BP monitoring crucial for accurate assessment. 3Management
Blood Pressure Control: Target mean arterial pressure <92 mm Hg to slow GFR decline. 4
Antihypertensive Agents:
- Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors): Initial treatment option, e.g., ramipril 2.5-10 mg/d. 4
- Angiotensin Receptor Blockers (ARBs): Consider as alternatives if ACE inhibitors are contraindicated.
- Calcium Channel Blockers: Such as amlodipine 5-10 mg/d, used as initial therapy in some trials. 4
Additional Measures: Control of proteinuria, management of comorbidities like diabetes, and lifestyle modifications.Special Populations
Renal Artery Stenosis: Consider coexisting renal artery stenosis in patients with elevated renin levels and resistant hypertension; interventions may include nephrectomy or renal autotransplantation. 5Key Recommendations
Achieve Strict Blood Pressure Control: Target mean arterial pressure <92 mm Hg to mitigate CKD progression. (Evidence: Strong 4)
Utilize Ambulatory Blood Pressure Monitoring: Essential for accurate assessment of hypertension control in patients with CKD. (Evidence: Moderate 3)
Initiate with ACE Inhibitors or ARBs: Use ACE inhibitors (e.g., ramipril 2.5-10 mg/d) or ARBs as first-line therapy for blood pressure management in hypertensive CKD. (Evidence: Strong 4)
Consider Coexisting Pathologies: Evaluate for additional renal lesions like renal artery stenosis in patients with resistant hypertension and elevated renin levels. (Evidence: Expert opinion 5)References
1 Sun X, Chen S, Zhao Y, Wu T, Zhao Z, Luo W et al.. OTUD6A in tubular epithelial cells mediates angiotensin II-induced kidney injury by targeting STAT3. American journal of physiology. Cell physiology 2024. link
2 Heras Benito M. Nephroangiosclerosis: an update. Hipertension y riesgo vascular 2023. link
3 Pogue V, Rahman M, Lipkowitz M, Toto R, Miller E, Faulkner M et al.. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension (Dallas, Tex. : 1979) 2009. link
4 Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al.. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002. link
5 Turini D, Selli C, Nicita G, Fiorelli C. Coexistence of renal artery stenosis and uretheropelvic junction obstruction in hypertensive patients with elevated renin. The Journal of urology 1979. link56846-9)